🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

247 results for “Pari Pharma GmbH” Clear

  1. MOXIFLOXACIN, CLOFAZIMINE, PRETOMANID, LINEZOLID, BEDAQUILINE

    Pari Pharma GmbH

    Patients diagnosed at the study sites with rifampicinresistant tuberculosis during the recruitment period will be evaluated for study inclusion.

    phase 3 small molecule active

    1 trial

  2. MYCOPHENOLATE MOFETIL, PREDNISOLONE , MYCOPHENOLATE MOFETIL, AZATHIOPRINE, Gazyvaro 1,000 mg concentrate for solution for infusion., AZATHIOPRINE

    Pari Pharma GmbH

    lupus nephritis

    phase 3 small molecule active

    1 trial

  3. Metalyse 5 000 units (25 mg) powder for solution for injection

    Pari Pharma GmbH

    Adult patients with a LVOS with large core within 9 hours of symptoms onset or last seen well, or with a diffusion weighted imaging (DWI)-fluid attenuated inversion recovery (FLAIR) mismatch in case of unknown onset.

    phase 3 small molecule active

    1 trial

  4. Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Placebo of methylprednisolone (glucose 5%), placebo of prednisone, PREDNISONE ARROW 20 mg, comprimé sécable

    Pari Pharma GmbH

    Patients presenting with acute myocarditis proven by cardiac magnetic resonance imaging (CMRi) or by histological evidence on endomyocardial biopsy (EMB)

    phase 3 small molecule active

    1 trial

  5. NIFEDIPINE, Placebo of Nifedipine

    Pari Pharma GmbH

    obstetric_pathological delivery

    phase 3 small molecule active

    1 trial

  6. NaCl 0.9%, DEXAMETHASONE

    Pari Pharma GmbH

    Cervicobrachial Neuralgia

    phase 3 small molecule active

    1 trial

  7. NaCl 0.9%, PREDNISONE ARROW 20 mg, comprimé sécable, METHYLPREDNISOLONE , Placebo de prednisone ARW 20 mg - Hydrogénophosphate de calcium dihydraté (94%) Stéarate de magnésium (1%) Amidon de maïs Lycatab C (5%), Glucose 5%

    Pari Pharma GmbH

    Erythema multiforme (EM) in its severe form managed at the hospital

    phase 3 small molecule active

    1 trial

  8. NaCl 0.9%, TRANEXAMIC ACID, TERLIPRESSIN

    Pari Pharma GmbH

    Hemoptysis, whatever the cause, with the exception of cystic fibrosis

    phase 3 small molecule active

    1 trial

  9. Neofordex 40 mg tablets, IMMUNOGLOBULINS, NORMAL HUMAN, FOR INTRAVASCULAR ADM., PREDNISONE

    Pari Pharma GmbH

    Adult patients with immune thrombocytopenia (ITP) with mild to severe bleeding manifestations

    phase 3 small molecule active

    1 trial

  10. Nucala 100 mg powder for solution for injection, IMUREL 25 mg, comprimé pelliculé, CYCLOPHOSPHAMIDE, SODIUM CHLORIDE, PLACEBO D AZATHIOPRINE

    Pari Pharma GmbH

    Eosinophilic granulomatosis with polyangiitis (EGPA), formerly called Churg-Strauss syndrome

    phase 3 small molecule active

    1 trial

  11. OBINUTUZUMAB, RITUXIMAB

    Pari Pharma GmbH

    Idiopathic nephrotic syndrome (INS)

    phase 3 small molecule active

    1 trial

  12. ONDANSETRON, IRINOTECAN, CALCIUM FOLINATE, CALCIUM LEVOFOLINATE, FLUOROURACIL, METHYLPREDNISOLONE

    Pari Pharma GmbH

    patient with colorectal cancer with hepatic metastasis

    phase 3 small molecule active

    1 trial

  13. Olumiant 4 mg film-coated tablets, Placebo of Olumiant 4mg

    Pari Pharma GmbH

    Dermatomyositis; Baricitinib in patients with relapsing or naïve dermatomyositis.

    phase 3 small molecule active

    1 trial

  14. PEGASPARGASE

    Pari Pharma GmbH

    This is a prospective, French, multicenter, open-label, design, stratified on the immunophenotypic characterization (B- or T- lineage) and the patient risk group, that aims at evaluating the efficacy and the tolerance of different schedules of pegaspargase in patients from 12 months to less than 18 years newly diagnosed with standard/medium-risk ALL

    phase 3 small molecule active

    1 trial

  15. PEMETREXED , KEYTRUDA 25 mg/mL concentrate for solution for infusion., CARBOPLATIN

    Pari Pharma GmbH

    Adult patients with stage IV non squamous non-small cell lung cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  16. PENTHROX 99,9%, liquide pour inhalation par vapeur de 3 mL, MORPHINE

    Pari Pharma GmbH

    Acute Myocardial Infarction

    phase 3 small molecule active

    1 trial

  17. PIPERACILLIN AND BETA-LACTAMASE INHIBITOR , NEGABAN 2 g, poudre pour solution injectable/pour perfusion, MEROPENEM ARROW 1 g, poudre pour solution injectable / pour perfusion

    Pari Pharma GmbH

    patients hospitalized in ICU with ESBL-producing Enterobacteriaceae severe infection

    phase 3 small molecule active

    1 trial

  18. PIPERACILLINE TAZOBACTAM VIATRIS 4 g/0,5 g, poudre pour solution pour perfusion, CEFAZOLIN, Placebo de Cefazoline / Piperaciline / Tazobactam

    Pari Pharma GmbH

    Excision-autograft surgery in burn patient

    phase 3 small molecule active

    1 trial

  19. PLACEBO DE COLCHICINE 1 mg, COLCHICINE OPOCALCIUM 1 mg, comprimé sécable

    Pari Pharma GmbH

    patients suffering from acute myocarditis confirmed on Cardiac magnetic resonance imaging.

    phase 3 small molecule active

    1 trial

  20. PLACEBO OF BELIMUMAB, Benlysta 200 mg solution for injection in pre-filled pen.

    Pari Pharma GmbH

    Adult patients with persistent or chronic immune thrombocytopenia

    phase 3 small molecule active

    1 trial

  21. PLACEBO OF VANCOMYCINE = NaCl 0.9% ( oral use ), Vancomycine Viatris 500 mg poudre pour solution pour perfusion

    Pari Pharma GmbH

    Patients hospitalized for allogeneic hematopoietic stem cell transplantation

    phase 3 small molecule active

    1 trial

  22. PREDNISONE, PREDNISONE , HYDROXYCHLOROQUINE

    Pari Pharma GmbH

    Sarcoidosis

    phase 3 small molecule active

    1 trial

  23. PREVYMIS 240 mg film-coated tablets, Placebo of prevymis 240 mg tablets (letermovir), VALGANCICLOVIR

    Pari Pharma GmbH

    CytoMegaloVirus infections, Kidney transplant

    phase 3 small molecule active

    1 trial

  24. PRISTINAMYCIN , AMOXICILLIN , CEFTRIAXONE , LEVOFLOXACIN , AMOXICILLIN AND BETA-LACTAMASE INHIBITOR , CEFOTAXIME PANPHARMA 1 g, poudre pour solution injectable (IM-IV), -

    Pari Pharma GmbH

    Community-acquired pneumonia

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources